Followers | 2733 |
Posts | 55279 |
Boards Moderated | 4 |
Alias Born | 08/10/2012 |
Wednesday, July 27, 2022 9:07:37 AM
ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study.
Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate that the dosing of Ketamine using a patent protected delivery system with Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study.
Eric Weisblum, CEO of Silo Pharma, commented, “These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction. This data is extremely promising for patients suffering from Fibromyalgia and Rheumatoid Arthritis. Additionally, I am delighted to report that Day seven and Day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.”
About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com
Safe Harbor and Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.
Investor Relations Contact:
Hayden IR
Brett Maas
646-536-7331
Email: brett@haydenir.com
https://finance.yahoo.com/news/silo-pharma-announces-positive-results-121500306.html
Recent SILO News
- Silo Pharma Announces Positive Results for Intranasal PTSD Treatment • GlobeNewswire Inc. • 04/23/2024 12:15:00 PM
- Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic • GlobeNewswire Inc. • 04/10/2024 12:11:00 PM
- Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic • GlobeNewswire Inc. • 03/20/2024 12:30:00 PM
- Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain • GlobeNewswire Inc. • 03/18/2024 11:15:00 AM
- Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD • GlobeNewswire Inc. • 02/28/2024 01:25:00 PM
- Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery • GlobeNewswire Inc. • 02/14/2024 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 06:15:35 PM
- Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology • GlobeNewswire Inc. • 02/01/2024 03:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/31/2024 05:15:16 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:29:45 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/25/2024 10:27:04 PM
- Silo Pharma Announces Positive Results in Alzheimer’s Disease Study • GlobeNewswire Inc. • 01/24/2024 01:55:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/23/2024 10:01:06 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/11/2024 05:15:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 09:30:11 PM
- Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD • GlobeNewswire Inc. • 01/04/2024 01:55:00 PM
- Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia • GlobeNewswire Inc. • 12/28/2023 01:25:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/21/2023 09:13:38 PM
- Form 8-K12B - Notification that a class of securities of successor issuer is deemed to be registered pursuant to section 12(b) • Edgar (US Regulatory) • 12/20/2023 09:58:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:44:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 09:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/07/2023 11:13:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:05:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 09:55:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/01/2023 02:10:20 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM